Vusolimogene Oderparepvec

Patient Education Sheets
Understanding Your Cancer Treatment

Care Team Contact Information: _____

Pharmacy Contact Information: _____

Diagnosis: _____

- This treatment is used for a type of skin cancer called melanoma.
- It may also be used for other reasons.

Goal of Treatment: _____

- Treatment may continue for a certain time period, until it no longer works, or until side effects are no longer controlled.

Treatment Regimen

Treatment Name	How the Treatment Works	How the Treatment is Given
Vusolimogene Oderparepvec (voo-soh-LIM-oh-jeen OH-der-pair-EP-vek): Tudriqev (TOO-drih-kev)	Slows down or stops the growth of cancer cells by using a modified virus that directly kills cancer cells and boosts the immune system.	Injection directly into the tumor (intratumoral).

Treatment Administration and Schedule

- Treatment is typically repeated every 2 weeks. This length of time is called a “cycle.” You may receive up to 8 cycles of vusolimogene oderparepvec.
- Vusolimogene oderparepvec is often given in combination with other treatments. Talk with your care team about your exact treatment and schedule.

	Cycle 1								Next Cycle
Treatment Name	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	…	Day 14	Day 1
Vusolimogene oderparepvec	✓								✓

Appointments

Appointments may include regular check-ups with your care team, treatment appointments, lab visits, and imaging tests. It's important to keep your appointments whenever you can. If you miss an appointment, call your care team as soon as possible to reschedule it.

Supportive Care to Prevent and Treat Side Effects

Description	Supportive Care Given at the Clinic or Hospital	Supportive Care Taken at Home
Supportive care used to treat or prevent side effects		

Brought to you by: ACCC Association of Cancer Care Centers; HOPA Hematology/Oncology Pharmacy Association; NCODA Network for Collaborative Oncology Development & Advancement; ONS Oncology Nursing Society

Common Side Effects

Side Effect	Important Information
Low Red Blood Cell (RBC) Count and Hemoglobin (Hgb) (Anemia)	Description: Red blood cells carry oxygen throughout your body. Low levels can make you feel tired, weak, dizzy, or short of breath. Recommendations: • Aim for 7 to 8 hours of sleep each night. • Do not drive, operate heavy machinery, or do other dangerous activities if you are very tired. • Balance activity and rest — stay as active as you can, but rest when needed. • Eat a balanced diet and follow any nutrition or supplement advice from your care team. Talk to your care team if you have: • Shortness of breath • Dizziness or fainting • Fast or irregular heartbeats • Sudden or severe headache
Infections	Description: Treatment may increase your chance of getting an infection. Recommendations: • Wash your hands often and bathe regularly. • Avoid crowded places and close contact with people who are sick. • Keep any catheter/port site clean and dry. Follow all instructions provided by your care team. Talk to your care team if you have: • Fever of 100.4°F (38°C) or higher • Chills • New or worsening cough or sore throat • Painful urination or signs of a urinary infection • Feeling much more tired than usual • Red, swollen, warm, or painful areas on the skin (possible skin infection)
Fever and Chills	Description: Fever is common with this treatment. Recommendations: • Take your temperature with a thermometer if you feel like you have a fever. • Your care team may recommend medicines for fever. Talk to your care team if you have: • Fever of 100.4°F (38°C) or higher • Fever lasting for more than 3 days • Any signs of infections, such as persistent cough, shortness of breath, or pain

Brought to you by: ACCC Association of Cancer Care Centers™ HOPA Hematology/Oncology Pharmacy Association NCODA Network for Collaborative Oncology Development & Advancement ONS Oncology Nursing Society

<table>
<tr><td>Fatigue</td><td>Description: Fatigue is a constant and sometimes strong feeling of tiredness.

Recommendations:
Routine exercise can help reduce fatigue. Talk with your care team to find the right type and amount of activity for you.
Ask family and friends for help with daily tasks and for emotional support.
Try healthy ways to feel better, such as meditation, journaling, yoga, or guided imagery, to reduce anxiety and improve well-being.
Aim for 7 to 8 hours of sleep each night. Limit daytime naps to help you sleep better at night.
Do not drive, operate heavy machinery, or do other potentially dangerous activities if you are very tired.
Talk to your care team if you have:
Tiredness that affects your daily life or prevents you from doing normal activities
Tiredness that does not get better with rest
Dizziness or weakness along with severe tiredness</td></tr>
<tr><td>Muscle, Bone, or Joint Pain</td><td>Description: Muscle pain is soreness, aching, cramps, stiffness, tenderness, or weakness in one or more muscles. Joint pain is pain, stiffness, swelling, or reduced movement where two bones meet. Bone pain is a deep, aching or sharp pain in or around a bone that may worsen with movement or pressure.

Recommendations:
Keep a pain diary: note pain levels, locations, and activities that make it better or worse.
Do gentle exercise (walking, stretching, yoga) to maintain mobility and strength. Check with your care team before starting a new activity.
Use a warm compress for stiff muscles or a cold pack to reduce swelling and numb pain—use what helps the area.
Your care team may recommend or prescribe medicines, including over-the-counter pain relievers.
Talk to your care team if you have:
Pain you cannot control with usual measures
Swelling, redness, or warmth in a joint
New weakness
Trouble walking or moving</td></tr>
</table>

Brought to you by: ACCC Association of Cancer Care Centers, HOPA Hematology/Oncology Pharmacy Association, NCODA Network for Collaborative Oncology Development & Advancement, ONS Oncology Nursing Society

Select Rare Side Effects

Side Effect	Talk to Your Care Team if You Have Any of These Signs or Symptoms
Herpes Infection or Reactivation	Vusolimogene oderparepvec is made from a modified herpes simplex virus type 1 (HSV-1), which commonly causes cold sores. It may cause a new herpes infection or cause a previous herpes infection to become active again. Herpes may cause sores around your mouth, genital area, or other parts of your body. The virus may also spread to other people through direct contact with the injection site, dressings, or body fluids. Avoid touching or scratching the injection site and keep it covered as directed by your care team. Caregivers should wear gloves when changing dressings. Tell your care team if you have had a herpes infection in the past. • New cold sores or blisters on or around your lips or mouth • Blisters or sores around your genital area • Small bumps that turn into blisters or sores on other parts of your body
Injection Procedure Complications	Serious problems can happen during or after vusolimogene oderparepvec injection, including bleeding, infection, or injury to nearby organs. Injections into tumors in the lung may cause a collapsed lung (pneumothorax). • Fever of 100.4°F (38°C) or higher • Chills • Increasing redness, swelling, warmth, or pain at the injection site • Heavy or uncontrolled bleeding • New or worsening chest pain • Shortness of breath or trouble breathing • Coughing up blood

Before starting treatment, ask your care team when to call 9-1-1 or seek emergency help.
If you experience any new, worsening, or uncontrolled side effects, contact your care team immediately.

Intimacy, Pregnancy, and Breastfeeding

- Treatment may **change how you feel about intimacy and your body.** However, physical closeness—such as holding hands and hugging—remains safe. It is common to have questions about intimacy. If needed, talk to your care team for guidance.
- Treatment may **harm an unborn baby**.
  - If you are able to become pregnant:
    - Your care team will verify your pregnancy status before treatment.
    - Use an effective method of birth control during treatment and for 90 days after your last dose of vusolimogene oderparepvec.
    - If you think you might be pregnant or if you become pregnant, tell your care team right away.
  - If your partner is able to become pregnant, use an effective method of birth control—such as condoms—during treatment and for 90 days after your last dose of vusolimogene oderparepvec.
- **Do not breastfeed** during treatment and for 90 days after your last dose of vusolimogene oderparepvec.

Brought to you by: ACCC Association of Cancer Care Centers, HOPA Hematology/Oncology Pharmacy Association, NCODA Network for Collaborative Oncology Development & Advancement, ONS Oncology Nursing Society

Additional Information

- **Tell your care team about all the medicines you take**.
  This includes prescriptions, over-the-counter drugs, vitamins, and herbal products. Before starting any new medicine, supplement, or vaccine, ask your care team first.
- **Keep your injection sites covered for at least 48 hours after treatment with vusolimogene oderparepvec**. This helps prevent the spread of HSV-1 to other people.
  - Avoid touching or scratching the injection sites or dressings.
  - If a dressing falls off, replace it with a new one.
  - Wear gloves when removing or changing dressings.
  - Wash your hands well with soap and water before and after changing dressings.
  - Place used dressings, gloves, and cleaning materials in a sealed plastic bag before throwing them in the household trash.
  - Avoid direct contact with injection sites, dressings, or body fluids.
  - If accidental contact occurs, wash the affected area well with soap and water.
- **This Patient Education Sheet may not describe all possible side effects.**
  Call your care team for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Notes

Updated Date: October 26, 2026

Brought to you by:
ACCC ASSOCIATION OF CANCER CARE CENTERS™
HOPA Hematology/Oncology Pharmacy Association
NCODA Network for Collaborative Oncology DEVELOPMENT & ADVANCEMENT
ONS Oncology Nursing Society

Scan the QR code below to access this education sheet.

Important Notice:
The Association of Cancer Care Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), Network for Collaborative Oncology Development & Advancement, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated to gather information and develop this patient education guide. This guide is a summary of the medication, based on information provided by the drug manufacturer and other sources.

This guide does not cover all information available on the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication. It should not be used as a substitute for the advice of a qualified healthcare professional. The provision of this guide is for informational purposes only. It does not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. All decisions regarding this medication should be made with the guidance and direction of a qualified healthcare professional.

Permission:
Patient Education Sheets are provided as a free educational resource for patients with cancer and their caregivers in need of concise, easy-to-understand information about cancer therapy. Healthcare providers may copy and distribute the sheets to patients and direct them to the Patient Education Sheets website. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holders. Permission requests, including direct linking from Electronic Health Records, and licensing inquiries should be emailed to patienteducationsheets@ncoda.org.

Copyright © 2026 by Network for Collaborative Oncology Development & Advancement, Inc. All rights reserved.

PES-701

Brought to you by:
ACCC Association of Cancer Care Centers
HOPA Hematology/Oncology Pharmacy Association
NCODA Network for Collaborative Oncology Development & Advancement
ONS Oncology Nursing Society